Pennsylvania-based healthcare provider Geisinger Health wants to make DNA sequencing routine at its hospitals and clinics, despite lingering questions about who would pay for the tests. Officials at the company said a pilot programme would be launched in the next six months, taking in 1,000 patients, before being expanded to facilities in the state and southern New Jersey. The move comes as companies such as 23andMe are trying to expand their reach into healthcare.
Pennsylvania-based healthcare provider Geisinger Health wants to make DNA sequencing routine at its hospitals and clinics, despite lingering questions about who would pay for the tests. Officials at the company said a pilot programme would be launched in the next six months, taking in 1,000 patients, before being expanded to facilities in the state and southern New Jersey. The announcement was made on the same day the National Institutes of Health launched its precision medicine initiative, aiming to collect the genomic data from one million US people.